Merck 2025 sales forecast underwhelms as it pauses Gardasil sales in China
Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...
Merck shares plunge as company pauses Gardasil vaccine shipments in China, hurting 2025 outlook
Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...
Merck Shares Hit After Guidance Falls Short, Gardasil Challenge
The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...
Merck stops Gardasil shipments to China, hitting 2025 outlook; shares tumble
Merck said on Tuesday it would not ship its HPV vaccine Gardasil in China until at least the middle of this year due to weak ...
Merck stock price target lowered to $95 by Bernstein SocGen
Bernstein SocGen Group has revised its price target for Merck (NYSE:MRK) shares, bringing it down to $95 from the previous $110 while maintaining a Market Perform rating. Analyst Courtney Breen cited ...
FiercePharma6d
Merck halts Gardasil shipments to China, withdraws $11B sales target as demand nosedives
The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...
Merck (MRK) Downgraded by TD Cowen Over Keytruda, Gardasil Concerns
We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a ...
Merck's Gardasil Vaccine Slowdown In China Bites Again, Stock Falls On Weak 2025 Outlook
Merck posted Q4 sales of $15.62 billion, driven by Keytruda's 19% growth. FY25 guidance lags estimates, citing Gardasil ...
Exclusive: Kennedy played key role in Gardasil vaccine case against Merck
Robert F. Kennedy Jr., who awaits confirmation as Donald Trump's Health and Human Services secretary, helped organize mass ...
STAT6d
Merck’s earnings miss focused attention on Gardasil. The real issue is Keytruda
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...
Merck Earnings: Gardasil Weighs on 2025 Growth, but Firm Still Undervalued
Merck’s MRK fourth-quarter revenue grew 7% to $15.6 billion (including Keytruda growth of 21% to $7.8 billion), in line with ...
Merck’s Gardasil Halt Shows Blockbuster Shots’ Dilemma in China
Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the cancer-preventing shot quickly deflated last year, to the point the US ...